Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Executive Summary
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
You may also be interested in...
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews
The latest drug development news and highlights from our US FDA Performance Tracker.
2018 Preparation: PD-1 Predictions And Commercialization Challenges
What's next for the PD-1 market, a cancer therapy area that exploded in 2017 as recently launched products secured ever more approvals? Maria Whitman, managing principal at sales and marketing firm ZS Associates, talks about challenges facing the booming immuno-oncology market and shares her predictions for 2018.